Jasper Therapeutics’ $50 Million Common Stock Offering

Paul Hastings LLP advised Jasper Therapeutics, Inc., while DLA Piper advised the underwriters. Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company focused on developing novel…

This content is for Standard 1 Year members only.
Login Join Now
Sonia Carcano

Author: Sonia Carcano

This content is for Standard 1 Year members only.
Login Join Now